The Thermogenesis Corporation has signed a distribution agreement with Dideco SpA to begin immediate commercialization of its CryoSeal Fibrin Sealant (FS) System in Europe, Eastern Europe, portions of Scandinavia and the Middle East, and Africa, according to a company press release.
The new system radically reduces Mad Cow concerns by providing a fibrin sealant sourced from either the patient's own blood or from a single donor without any bovine additive. The company believes the worldwide market for fibrin sealant is about $500 million a year, of which $100 million is consumed by Europe alone.
As part of its contract evaluation process, Dideco conducted human clinical studies on the CryoSeal FS system over a six-month period. After extensive research, Thermogenesis Corp's newly introduced technology platforms lead the world in their ability to produce biotherapeutic products from single units of blood.
Dideco SpA, a Snia Group company located in Mirandola, Italy, manufactures a complete line of products for the surgical blood processing for adults and children. — (menareport.com)
© 2002 Mena Report (www.menareport.com)
